The company is also advancing commercial preparations for COMP360 in treatment-resistant depression (TRD), aiming to be ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, COMPASS Pathways plc (NASDAQ:CMPS) has a ‘Buy’ or equivalent rating from the majority of ...

The field of psychedelic medicine is relatively new, and because of this, certain investors consider it to be loaded with potential. That's why even minor events in companies specializing in this can ...

Compass Pathways (CMPS), on Wednesday, said the U.S. Food and Drug Administration (FDA) has accepted its Investigational New ...

Shares of Compass Pathways Plc (NASDAQ:CMPS) rose about 3% in premarket trading on Wednesday after the company said the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND ...

Compass Pathways Plc (CMPS) stock has reached a 52-week low, trading at $4.25. This price point marks the lowest level the stock has traded at over the past year, reflecting a period of significant ...

Compass Pathways Plc (NASDAQ: CMPS) stock has reached a new 52-week low, touching down at $2.87, marking a 73% decline from its 52-week high of $10.31. According to InvestingPro data, the company ...

Compass Pathways Plc (NASDAQ: CMPS) stock has reached a new 52-week low, touching down at $3.15, representing a dramatic 70% decline from its 52-week high of $10.31. This latest price point marks a ...

COMPASS Pathways PLC Sponsored ADR (CMPS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

As of 12:32:25 pm GMT+2. Market open. (Bloomberg) -- Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial.Most ...